TY - JOUR
T1 - High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism
AU - Poli, Daniela
AU - Zanazzi, Maria
AU - Antonucci, Emilia
AU - Marcucci, Rossella
AU - Rosati, Alberto
AU - Bertoni, Elisabetta
AU - Salvadori, Maurizio
AU - Liotta, Agatina Alessandrello
AU - Abbate, Rasanna
AU - Prisco, Domenico
AU - Gensini, Gian Franco
PY - 2005/9/27
Y1 - 2005/9/27
N2 - Background. No data are available about the optimal duration of oral anticoagulant therapy (OAT) after an episode of venous thromboembolism (VTE) occurring in renal transplant (RT) recipients. Our study was undertaken to evaluate the risk of VTE recurrence in patients developing a first episode of VTE after RT. Methods. Among 484 RT patients, 34 (7%) developed a first VTE: 28/34 VTE patients (Group 1) were prospectively studied, after stopping OAT. Group 1 was compared with a group of 84 patients without history of renal disease who had suffered from a first episode of VTE matched for age, sex and type of thrombotic event (Group 2) and with a matched group of 84 RT recipients with no history of VTE (Group 3). After OAT withdrawal, blood samples were obtained for thrombophilia and clotting activation markers (prothrombin fragment 1+2 (F1+2) and D-dimer plasma levels). Results. During follow-up, 14/28 patients of Group 1 and 8/84 patients of Group 2 experienced VTE recurrence (P
AB - Background. No data are available about the optimal duration of oral anticoagulant therapy (OAT) after an episode of venous thromboembolism (VTE) occurring in renal transplant (RT) recipients. Our study was undertaken to evaluate the risk of VTE recurrence in patients developing a first episode of VTE after RT. Methods. Among 484 RT patients, 34 (7%) developed a first VTE: 28/34 VTE patients (Group 1) were prospectively studied, after stopping OAT. Group 1 was compared with a group of 84 patients without history of renal disease who had suffered from a first episode of VTE matched for age, sex and type of thrombotic event (Group 2) and with a matched group of 84 RT recipients with no history of VTE (Group 3). After OAT withdrawal, blood samples were obtained for thrombophilia and clotting activation markers (prothrombin fragment 1+2 (F1+2) and D-dimer plasma levels). Results. During follow-up, 14/28 patients of Group 1 and 8/84 patients of Group 2 experienced VTE recurrence (P
KW - Oral anticoagulant therapy
KW - Renal transplant recipients
KW - Venous thromboembolism
KW - Venous thromboembolism recurrence
UR - http://www.scopus.com/inward/record.url?scp=26644474947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26644474947&partnerID=8YFLogxK
U2 - 10.1097/01.TP.0000174168.00730.B4
DO - 10.1097/01.TP.0000174168.00730.B4
M3 - Article
C2 - 16210966
AN - SCOPUS:26644474947
VL - 80
SP - 789
EP - 793
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 6
ER -